Acuitas Therapeutics Named One of BC’s Top Employers
VANCOUVER, BC – Acuitas Therapeutics, Inc. was recently named one of BC’s Top Employers of 2024. The Vancouver-based, privately held biotechnology firm is the global leader in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles.
“We are honoured to be named as one of BC’s Top Employers,” said President & CEO Dr. Thomas Madden. He added: “The foundation of our success is a work culture where everyone feels respected, heard and valued. We have some of the world’s best scientists and business professionals on our team, and we are dedicated to the transformative power of science – in our case, biotechnology – to improve lives. Our scientific innovation attracts exceptional talent, and our culture of innovation and collaboration retains them. It is a great combination.”
About Acuitas Therapeutics
Vancouver-based Acuitas Therapeutics (www.acuitastx.com) partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical development and commercialization. Acuitas’ lipid nanoparticle (LNP) technology is clinically validated, enabling Alnylam Pharmaceuticals’ ONPATTRO® for the treatment of people with a rare genetic and otherwise fatal disorder known as transthyretin amyloidosis and the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in over 180 countries. More recently, in partnership with Verve Therapeutics, scientists at Acuitas helped to enable the first human proof-of-concept for genome base editing to treat a serious genetic disease. The company is currently focused on further innovations to its LNP carriers to advance the development of novel gene therapies, such as epigenetic medicines, to modulate gene expression without genetic editing to treat a range of diseases, including cancer. In addition, Acuitas works with partners on the development of improved vaccines – such as multi-valent vaccines to prevent a range of infectious diseases (including malaria, HIV/AIDS and tuberculosis) – and on novel therapeutic vaccines against cancer, including personalized cancer vaccines.
Original source here.